Literature DB >> 2671555

Mucosal leishmaniasis in Brazil.

J T Zajtchuk1, J D Casler, E M Netto, M Grogl, R C Neafie, C R Hessel, A V de Magalhaes, P D Marsden.   

Abstract

The clinical diagnosis and laboratory identification of Leishmania braziliensis braziliensis, a parasitic disease affecting the upper aerodigestive tract, is difficult. A retrospective computer-assisted analysis of patient records was done after examination of 58 patients with mucosal leishmaniasis in an endemic area of L. braziliensis braziliensis in Bahia, Brazil during January 1987. Biopsies of clinically active and clinically inactive mucosal patients were examined for parasites using routine hematoxylin and eosin histopathology and a new technique for rapid detection of Leishmania amastigotes using a genus-specific indirect immunofluorescent assay. No amastigotes were found in specimens from seven patients with clinically inactive mucosal disease using immunofluorescent monoclonal assay techniques, whereas specimens from seven out of 14 patients with clinically active mucosal disease were positive. These results suggest that the immunofluorescent antibody technique is markedly superior in identifying the intracellular amastigote in tissue sections of mucosal biopsies when compared to histopathology techniques or with other standard tests done in rural areas of Brazil. Various clinical and laboratory test data of the entire group of patients were examined and the efficacy of treatment evaluated. The median interval of time noted between cutaneous and mucosal disease was 4.5 years. Relapse was noted in 31% of patients treated with a low dose of meglumine antimoniate (10 mg per kg of body weight). Patients treated with a high dose of meglumine antimoniate (20 mg per kg of body weight) had a relapse rate of 27.3%. A chi-square statistical analysis revealed no significant difference (chi 2 = 0.049) between the two groups. Patients were considered cured if mucosal granulations were clinically absent after 4.6 years.

Entities:  

Mesh:

Year:  1989        PMID: 2671555     DOI: 10.1288/00005537-198909000-00006

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  11 in total

1.  Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?

Authors:  A Gomes-Silva; R de Cássia Bittar; R Dos Santos Nogueira; V S Amato; M da Silva Mattos; M P Oliveira-Neto; S G Coutinho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

2.  Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).

Authors:  Erica de Camargo Ferreira E Vasconcellos; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhaes de Oliveira; Rilza Beatriz Azeredo-Coutinho; Fátima da Conceição Silva; Mariza de Matos Salgueiro; João Soares Moreira; Maria de Fátima Madeira; Cibele Baptista; Cláudia Maria Valete-Rosalino
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

3.  A proposed new clinical staging system for patients with mucosal leishmaniasis.

Authors:  Hélio A Lessa; Marcus M Lessa; Luiz Henrique Guimarães; Clara Mônica F Lima; Sergio Arruda; Paulo R Machado; Edgar M Carvalho
Journal:  Trans R Soc Trop Med Hyg       Date:  2012-05-11       Impact factor: 2.184

4.  Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia.

Authors:  Liliana Castillo-Rodríguez; Clemencia Ovalle-Bracho; Diana Díaz-Jiménez; Guillermo Sánchez-Vanegas; Sandra Muvdi-Arenas; Carlos Castañeda-Orjuela
Journal:  PLoS One       Date:  2019-11-04       Impact factor: 3.240

5.  A Cytokine Network Balance Influences the Fate of Leishmania (Viannia) braziliensis Infection in a Cutaneous Leishmaniasis Hamster Model.

Authors:  Milla B Paiva; Raquel Peralva Ribeiro-Romão; Larissa Resende-Vieira; Thais Braga-Gomes; Marcia P Oliveira; Andrea F Saavedra; Luzinei Silva-Couto; Hermano G Albuquerque; Otacilio C Moreira; Eduardo Fonseca Pinto; Alda Maria Da-Cruz; Adriano Gomes-Silva
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 6.  Comparative genomics: from genotype to disease phenotype in the leishmaniases.

Authors:  Deborah F Smith; Christopher S Peacock; Angela K Cruz
Journal:  Int J Parasitol       Date:  2007-06-23       Impact factor: 3.981

7.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27

8.  Leishmania braziliensis-reactive T cells are down-regulated in long-term cured cutaneous Leishmaniasis, but the renewal capacity of T effector memory compartments is preserved.

Authors:  Regina Pereira-Carvalho; Carolina O Mendes-Aguiar; Manoel P Oliveira-Neto; Cláudia J F Covas; Alvaro L Bertho; Alda M Da-Cruz; Adriano Gomes-Silva
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

9.  Antigen-triggered interferon-γ and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease.

Authors:  R S Nogueira; A Gomes-Silva; R C Bittar; D Silva Mendonça; V S Amato; M da Silva Mattos; M P Oliveira-Neto; S G Coutinho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 10.  Cutaneous Leishmaniasis Vaccination: A Matter of Quality.

Authors:  Paula Mello De Luca; Amanda Beatriz Barreto Macedo
Journal:  Front Immunol       Date:  2016-04-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.